Saturday, August 30, 2014 Last update: 10:03 AM
FreshNews.com - All Company Technology News Since 1996

BioLife Solutions Announces Sponsorship of Alliance for Regenerative Medicine 2nd Annual REGENMED Investor Day

Companies mentioned in this article: BioLife Solutions, Inc.

BOTHELL, Wash., March 10, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced that it is co-sponsoring the Alliance for Regenerative Medicine 2(nd) Annual REGENMED Investor Day, to be held March 26, 2014 at the Metropolitan Club in New York City.

This one-day, high-impact program will provide institutional investors and life science analysts with insight from the industry's leading small- and mid-cap companies. Through dynamic discussions between key opinion leaders, top analysts and senior executives, attendees will have exclusive access to the sector's leading stakeholders and hear the latest on the industry's prominent disease indications. Additionally, the field's most promising companies, both public and private, from across the globe will give focused presentations detailing a recent, major data-event.

Mike Rice, BioLife's Chief Executive Officer, remarked on the value of this event by stating, "As a corporate member of ARM, we support their mission and are encouraged by growing institutional and corporate strategic investment interest in ARM companies. We are very pleased to see that nearly half of the presenting companies at the conference are BioLife customers, currently using our clinical grade biopreservation media products in numerous clinical trials of new and potentially life-saving cellular therapies and products."

The recently published visiongain Translational Regenerative Medicine market research report forecasts that the regenerative medicine market comprised of cell and gene therapies and tissue-engineered products will grow to more than $23 billion by 2024. BioLife expects to participate in this market growth by providing biopreservation media and precision thermal packaging products used to store, freeze, ship, and administer clinical cells and tissues to patients. To date, BioLife's proprietary biopreservation media products have been incorporated into over 100 hospital-approved and clinical trial stage regenerative medicine products and therapies.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM)'s mission is to advance regenerative medicine by representing, supporting and engaging all stakeholders in the field, including companies, academic research institutions, patient advocacy groups, foundations, health insurers, financial institutions and other organizations.

Based in Washington, DC, ARM is a global advocacy organization that promotes legislative, regulatory, reimbursement, investment, technical and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understanding of the field and its potential to transform human healthcare.

Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. For more information please visit www.alliancerm.org.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and high performance thermal packaging products for cells, tissues, and organs. The Company's proprietary HypoThermosol(®) and CryoStor(®) platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets, where the products are currently utilized in more than 100 clinical trials and hospital-approved procedures. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our products' performance and market adoption, market forecasts, and other anticipated developments related to us, our business or customers. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

    Media & Investor Relations

    Daphne Taylor

    Senior Vice President, Chief Financial Officer

    (425) 402-1400

    dtaylor@biolifesolutions.com

SOURCE BioLife Solutions, Inc.